n 5 10), NHL (n 5 7), Hodgkin's lymphoma (n 5 6), advanced CML (n 5 4), and advanced CLL (n 5 4). 9 pts had previously undergone autografting. 80% received HLA-identical grafts. All pts were conditioned with fludarabine (30 mg/m 2 /day, days -7 to -3), busulfan (0.8 mg/kg/dose IV Â 8 doses) and rabbit ATG (2.5 mg/ kg/day, days -4 to -2) followed by micro-dose methotrexate and tacrolimus. Stem cell source included peripheral blood (n 5 26) or bone marrow (n 5 4). All pts engrafted neutrophils

more »

... platelets promptly (median 15 and 16 days, respectively). There were no primary graft failures. Rates of grade II-IV and III-IV aGVHD were 43% (n 5 13) and 23% (n 5 7) respectively. 9 pts (30%) developed cGVHD but extensive cGVHD was seen in only 10% (n 5 3). Day 100 TRM was 10% (n 5 3). CMV and EBV reactivation occurred in 30% (n 5 9) and 20% (n 5 6) respectively. 2 pts developed PTLD requiring rituximab. 3 pts had BK-virus associated hemorrhagic cystitis. Chimerism analysis showed 100% donor CD331 at all time points (days 30, 60, 100) and median donor CD31 chimerism of 94% at day 130 and 100% at day 1100. One pt had secondary graft failure. 23 pts (76%) were in CR after SCT. Kaplan-Meier estimates of overall survival (OS) and progression free survival (PFS) at 1 year are 62% and 43% respectively. OS (P 5 0.95) and PFS (P 5 0.65) was not statistically significant between recipients of matched and mismatched grafts. In conclusion, FBA and tacrolimus based GVHD prophylaxis achieved rapid donor chimerism and a favorably low incidence of TRM and cGVHD despite being tested in poor risk pts. However the rates of EBV reactivation and disease relapse warrant further exploration of this approach using lower doses of ATG (e.g. 5-6 mg/kg total dose).